info@ceoworld.biz
Thursday, March 28, 2024
CEOWORLD magazine - Latest - CEO Advisory - Canada’s Sernova Corp diabetes Cell Pouch System(TM) control device shows promise in pigs

CEO Advisory

Canada’s Sernova Corp diabetes Cell Pouch System(TM) control device shows promise in pigs

Canadian-based health sciences company, Sernova Corp (SVA) said its experimental glucose-control device showed safety and efficacy in a pre-clinical study in pigs that were made diabetic.

Dr. Philip Toleikis, Sernova’s President & CEO, noted “Our Cell Pouch System(TM) is a proprietary medical device implanted under the skin rapidly forming into a tissue-engineered, organ-like structure that provides a natural environment for the survival and function of therapeutic cells. These long-term results represent a significant achievement as a possible alternative to the current practice of injecting islets directly into the portal vein of the liver.”

“Our data are profound because they suggest the potential to reduce side-effects associated with the current standard of care and achieve glucose control with significantly fewer islets than normally required,” said Toleikis.

The Cell Pouch System(TM) was implanted in pigs which were then made diabetic through removing the pancreas and chemical induction. The animal’s own islets (Autograft) isolated from the pancreas were transplanted into the device. Standard measures of efficacy including fasting and non-fasting glucose levels, glucose tolerance tests (IVGTT), and C-peptide were taken up to 72 days post-transplant. At the end of the study period, the device containing the islets was removed and the animals returned to a diabetic state.

Sernova Corp. (TSX:V-SVA) is a Canadian-based medical device and combination product development company benefiting patients with chronic metabolic, neurological, and haematological diseases with a first product focus on diabetes, partaking in the near-term $8 billion cell therapy market.


Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.

This report/news/ranking/statistics has been prepared only for general guidance on matters of interest and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, CEOWORLD magazine does not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.


Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
SUBSCRIBE NEWSLETTER
CEOWORLD magazine - Latest - CEO Advisory - Canada’s Sernova Corp diabetes Cell Pouch System(TM) control device shows promise in pigs
Jessica Todd Swift
Jessica Todd Swift is the deputy managing editor of the CEOWORLD magazine. She is a veteran business and tech blogger, journalist, and analyst. Jessica is responsible for overseeing newsroom assignments and publishing and providing support to the editor in chief.